Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GOVX |
---|---|---|
09:32 ET | 469 | 1.52 |
09:36 ET | 3000 | 1.5365 |
09:45 ET | 1000 | 1.51 |
09:48 ET | 947 | 1.51 |
10:10 ET | 700 | 1.5299 |
10:21 ET | 120 | 1.5101 |
11:27 ET | 1807 | 1.49 |
11:42 ET | 182 | 1.5 |
11:44 ET | 8272 | 1.56 |
11:45 ET | 100 | 1.59 |
11:56 ET | 500 | 1.6843 |
11:58 ET | 150 | 1.5974 |
01:03 ET | 2013 | 1.55 |
01:10 ET | 3730 | 1.583 |
01:50 ET | 100 | 1.59 |
02:11 ET | 300 | 1.6 |
03:00 ET | 180 | 1.6466 |
03:39 ET | 307 | 1.6089 |
03:45 ET | 1882 | 1.52 |
03:57 ET | 300 | 1.55 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
GeoVax Labs Inc | 3.5M | -0.1x | --- |
Altamira Therapeutics Ltd | 3.2M | -0.1x | --- |
Burzynski Research Institute Inc | 3.4M | -3.9x | --- |
Mustang Bio Inc | 3.5M | -0.1x | --- |
Kiromic Biopharma Inc | 3.3M | -0.1x | --- |
Revelation Biosciences Inc | 3.7M | 0.1x | --- |
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.90 |
EPS | $-14.25 |
Book Value | $2.91 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.